1.13 USD
-0.01 (-0.88%)
We assign a fundamental rating of 2 out of 10 to TELA. TELA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. TELA may be in some trouble as it scores bad on both profitability and health. TELA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TELA has reported negative net income.
In the past year TELA has reported a negative cash flow from operations.
TELA had negative earnings in each of the past 5 years.
TELA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of TELA (-63.32%) is worse than 71.12% of its industry peers.
The Return On Equity of TELA (-2504.69%) is worse than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.32% | ||
| ROE | -2504.69% | ||
| ROIC | N/A |
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TELA has a better Gross Margin (67.23%) than 71.66% of its industry peers.
In the last couple of years the Gross Margin of TELA has grown nicely.
The Profit Margin and Operating Margin are not available for TELA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
2. Health
2.1 Basic Checks
TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
TELA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TELA has more shares outstanding
TELA has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -8.23, we must say that TELA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.23, TELA is doing worse than 77.54% of the companies in the same industry.
A Debt/Equity ratio of 26.65 is on the high side and indicates that TELA has dependencies on debt financing.
TELA has a worse Debt to Equity ratio (26.65) than 88.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 26.65 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.23 |
ROIC/WACCN/A
WACC8.38%
2.3 Liquidity
A Current Ratio of 3.30 indicates that TELA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.30, TELA is in line with its industry, outperforming 58.29% of the companies in the same industry.
TELA has a Quick Ratio of 2.62. This indicates that TELA is financially healthy and has no problem in meeting its short term obligations.
TELA has a Quick ratio of 2.62. This is in the better half of the industry: TELA outperforms 60.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 47.34% over the past year.
TELA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.24%.
TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.01% yearly.
EPS 1Y (TTM)47.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%9.14%
3.2 Future
TELA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.21% yearly.
The Revenue is expected to grow by 14.05% on average over the next years. This is quite good.
EPS Next Y38.59%
EPS Next 2Y25.25%
EPS Next 3Y19.66%
EPS Next 5Y18.21%
Revenue Next Year7.66%
Revenue Next 2Y11.37%
Revenue Next 3Y13.04%
Revenue Next 5Y14.05%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TELA. In the last year negative earnings were reported.
Also next year TELA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TELA's earnings are expected to grow with 19.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.25%
EPS Next 3Y19.66%
5. Dividend
5.1 Amount
TELA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TELA (12/19/2025, 8:18:07 PM)
1.13
-0.01 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners71.18%
Inst Owner Change0.73%
Ins Owners8.47%
Ins Owner Change0.42%
Market Cap49.46M
Revenue(TTM)77.06M
Net Income(TTM)-39.00M
Analysts81.82
Price Target3.52 (211.5%)
Short Float %1.07%
Short Ratio2.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.8%
Min EPS beat(2)-21.99%
Max EPS beat(2)6.39%
EPS beat(4)1
Avg EPS beat(4)-10.53%
Min EPS beat(4)-25.31%
Max EPS beat(4)6.39%
EPS beat(8)2
Avg EPS beat(8)-1.79%
EPS beat(12)5
Avg EPS beat(12)0.63%
EPS beat(16)5
Avg EPS beat(16)-3.48%
Revenue beat(2)0
Avg Revenue beat(2)-5.58%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.25%
Revenue beat(4)1
Avg Revenue beat(4)-7.97%
Min Revenue beat(4)-25.31%
Max Revenue beat(4)4.59%
Revenue beat(8)2
Avg Revenue beat(8)-5.8%
Revenue beat(12)2
Avg Revenue beat(12)-6.09%
Revenue beat(16)6
Avg Revenue beat(16)-4.2%
PT rev (1m)-25.81%
PT rev (3m)-36.11%
EPS NQ rev (1m)-1.02%
EPS NQ rev (3m)-12.02%
EPS NY rev (1m)-0.94%
EPS NY rev (3m)-6.33%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)-15.59%
Revenue NY rev (1m)-5.82%
Revenue NY rev (3m)-5.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 31.77 | ||
| P/tB | 480.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.76
BVpS0.04
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.32% | ||
| ROE | -2504.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.23% | ||
| FCFM | N/A |
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
F-Score4
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 26.65 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.56% | ||
| Cap/Sales | 0.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | -8.23 |
F-Score4
WACC8.38%
ROIC/WACCN/A
Cap/Depr(3y)110.61%
Cap/Depr(5y)96.68%
Cap/Sales(3y)2.33%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
EPS Next Y38.59%
EPS Next 2Y25.25%
EPS Next 3Y19.66%
EPS Next 5Y18.21%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%9.14%
Revenue Next Year7.66%
Revenue Next 2Y11.37%
Revenue Next 3Y13.04%
Revenue Next 5Y14.05%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.1%
EBIT Next 3Y17.88%
EBIT Next 5Y23.27%
FCF growth 1Y25.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.14%
OCF growth 3YN/A
OCF growth 5YN/A
TELA BIO INC / TELA FAQ
Can you provide the ChartMill fundamental rating for TELA BIO INC?
ChartMill assigns a fundamental rating of 2 / 10 to TELA.
What is the valuation status for TELA stock?
ChartMill assigns a valuation rating of 0 / 10 to TELA BIO INC (TELA). This can be considered as Overvalued.
Can you provide the profitability details for TELA BIO INC?
TELA BIO INC (TELA) has a profitability rating of 1 / 10.
How financially healthy is TELA BIO INC?
The financial health rating of TELA BIO INC (TELA) is 3 / 10.
Can you provide the expected EPS growth for TELA stock?
The Earnings per Share (EPS) of TELA BIO INC (TELA) is expected to grow by 38.59% in the next year.